SXTP · 60 Degrees Pharmaceuticals, Inc.
$0.92
0.00 (-0.28%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has evaluated these conditions and its plans to mitigate them and concluded that, collectively, such plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern for at least one year after the date these consolidated condensed financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$3.24M
Shares
3.52M
Volume · Oct 21
12.56K
Avg daily vol (3M)
130.09K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.92
Open$0.83
Day$0.81–1.00
52W close$0.83–6.00
Avg vol 30d176K
Short int133K · 3.8% float · 1.6d
Short vol33%
DataJul 2023–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.11M
Trailing 12 months
Net income (TTM)
−$8.11M
Trailing 12 months
Revenue growth YoY
+106.0%
Year over year
Operating margin
-774.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-305.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$872,576
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+620.7%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
3.8%
Latest settlement · 1.6 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−49%
below
Price vs 50-day avg
−12%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−11%
trailing
6-month return
−41%
trailing
YTD return
−55%
this year
Relative strength
−49%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
1 of 12 funds reported for Sep 30 · net +125.9K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.79% of float · ▼ -38.3% MoM · 1.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
12 holders — mid 3-yr range
Squeeze score
43
elevated · 0–100
Fundamentals
Revenue growth
+65%
Y/Y
Gross margin
22%
contracting
EPS growth
+84%
Y/Y
Free cash flow
$-7.0M
Balance sheet
$1.4M
net cash
Quant / Vol
risk profile
Volatility
198%
annualized · 1-yr
Max drawdown
−86%
past year
ATR
13.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−49%
Bearish
Price vs 50-day avg
−12%
Bearish
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
1 of 12 funds reported for Sep 30 · net +125.9K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.79% of float · ▼ -38.3% MoM · 1.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
12 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 2%
Range high $6
vs 200-day avg -49%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| 16-ct box equivalents sold to U.S. pharmacies and dispensaries | 1,287 | the three months ended June 30, 2026 filing | +18.9% |
|
|
|||
| 3PL share of total net product sales of Arakoda | 92% | the three months ended June 30, 2026 filing | — |
| Biocelect sell-through boxes (Australia) | 497 | the three months ended June 30, 2026 filing | +25.5% |
|
|
|||
| Infuserve America share of total net product sales of Arakoda | 0% | the three months ended June 30, 2026 filing | — |
| Kodatef Australian distributor share of total net product sales of Arakoda | 8% | the three months ended June 30, 2026 filing | — |
| Scandinavian Biopharma sell-through boxes (Europe) | 103 | the three months ended June 30, 2026 filing | -6.4% |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SXTP
this stock
60 Degrees Pharmaceuticals, Inc.
|
$3.24M | — | +65.5% | — | 3.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.39B | +13.5% | +46.2% | 30.2 | 1.8% |
|
MRNA
Moderna, Inc.
|
$96.65B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.13B | +4.6% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SXTP | +2.5% | -11.3% | -41.3% | -30.7% | -54.6% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | +3.6% | -10.8% | -49.3% | -31.5% | -67.4% |